Patents Assigned to Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.
-
Patent number: 9283095Abstract: Embodiments relate to systems and methods for magnetized stent having growth-promoting properties. A stent assembly comprising a tubular elongated body having a magnetized region and a tissue nidus area is inserted beneath the orifice of a vascular aneurysm. The magnetic region can serve to attract and position both residual red blood cells and magnetically nano-ireated growth-promoting cells to the orifice area of the aneurysm. The outer circumference of the tubular elongated body can act as a floor or scaffold for regenerated smooth vascular muscle cells. In embodiments, the tissue nidus area can be provided on the exterior stent, while the magnetized region is provided on the interior stent, of a stent-in-stent structure. In embodiments, the exterior stent is made of biodegradable material which gradually dissolves or dissipates in situ.Type: GrantFiled: July 6, 2011Date of Patent: March 15, 2016Assignee: The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.Inventor: Teodoro Aclan Tigno, Jr.
-
Patent number: 9234168Abstract: The invention provides methods of producing vaccines directed against microorganisms, with the methods comprising culturing, harvesting and/or suspending the microorganism in the presence of a radiation-protective composition and irradiating the bacteria or viruses with a dose of radiation sufficient to render the microorganism replication-deficient and/or non-infective. The radiation-protective compositions used in the methods of the present invention comprise at least one nucleoside, at least one antioxidant and at least one small peptide. The invention also provides methods of rendering bacteria in culture resistant to ionizing radiation (IR), with these methods comprising culturing the bacteria in the presence of a radiation-protective composition.Type: GrantFiled: April 29, 2011Date of Patent: January 12, 2016Assignee: The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.Inventors: Michael J. Daly, Elena K. Gaidamakova
-
Publication number: 20160003822Abstract: The present invention relates to methods and kits to assess an absorbed dose of ionizing radiation and/or the severity of tissue injury from radiation in a patient. The invention also relates to algorithms used to calculate an absorbed dose of radiation based on biomarker measurements of a plurality of biomarkers that are altered relative to a normal control in the event of radiation exposure.Type: ApplicationFiled: September 15, 2015Publication date: January 7, 2016Applicants: Meso Scale Technologies, LLC, The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.Inventors: William F. Blakely, Eli N. Glezer, John Kenten, Sudeep Kumar, Anu Mathew, Natalia I. Ossetrova, George Sigal
-
Patent number: 9206481Abstract: Alterations in ERG gene expression can be observed in patients with prostate cancer. Specific ERG isoforms are associated with, or involved in, prostate cancer. Compositions comprising these isoforms provide therapeutic benefit and can be used in methods of detecting, diagnosing, prognosing, and treating prostate cancer. These compositions provide biomarkers for detecting the expression of combinations of the PSA/KLK3, PMEPA1, NKX3.1, ODC1, AMD1, and ERG genes.Type: GrantFiled: April 10, 2008Date of Patent: December 8, 2015Assignee: The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.Inventors: Shiv Srivastava, Albert Dobi, Taduru Sreenath, Gyorgy Petrovics, Chen Sun
-
Patent number: 9205276Abstract: The present invention generally relates to a method of using light treatment supporting specific cell types in a subject. Specifically, the present invention relates to methods for stimulating the proliferation, migration, differentiation and survival of cell using specific parameter of lights. These methods are particularly useful in the cellular regeneration and replacement in a tissue injury, such as CNS or PNS injury, and in transplantation of organs, tissues and cells.Type: GrantFiled: March 30, 2006Date of Patent: December 8, 2015Assignees: THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC., THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND SERVICESInventors: Tara B. Romanczyk, Juanita J. Anders, Ronald R. Waynant, Ilko K. Ilev, Leonardo Longo
-
Patent number: 9186406Abstract: This invention encompasses methods of preserving protein function by contacting a protein with a composition comprising one or more purine or pyrimidine nucleosides (such as e.g., adenosine or uridine) and an antioxidant (such as e.g., manganese). In addition, the invention encompasses methods of treating and/or preventing a side effect of radiation exposure and methods of preventing a side effect of radiotherapy comprising administration of a pharmaceutically effective amount of a composition comprising one or more purine or pyrimidine nucleosides (such as e.g., adenosine or uridine) and an antioxidant (such as e.g., manganese) to a subject in need thereof. The compositions may comprise D. radiodurans extracts.Type: GrantFiled: August 18, 2008Date of Patent: November 17, 2015Assignees: The Henry M. Jackson Foundation for Advancement of Military Medicine, Inc., The United States of America, as Represented by the Secretary, Department of Health and Human Services, National Institutes of HealthInventors: Michael J. Daly, Elena K. Gaidamakova, Vera Y. Matrosova, Rodney L. Levine, Nancy B. Wehr
-
Publication number: 20150175660Abstract: The invention provides a method for the creation of peptide antigens comprising epitopes with at least a first modification comprising a shortened or lengthened amino acid side chain. By extension or shortening of the side chain with CH3/CH2 groups, for example, made by computer assisted modeling of the tumor antigen (peptide) bound in the MHC-I-groove, immunogenicity can be improved with minimal modification of adjacent tertiary structure, thereby avoiding cross-reactivity. Provided by the invention are methods of creating such antigens, as well as methods for therapeutic or prophylactic treatment of various conditions comprising administration of the antigens.Type: ApplicationFiled: July 29, 2014Publication date: June 25, 2015Applicants: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM, Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.Inventors: Constantin G. IOANNIDES, Martin L. CAMPBELL, Catherine A. O'BRIAN, George E. PEOPLES
-
Patent number: 9056902Abstract: This invention relates to soluble forms of G glycoprotein from Hendra and Nipah virus. In particular, this invention relates to compositions comprising soluble forms of G glycoprotein from Hendra and Nipah virus and also to diagnostic and therapeutic methods using the soluble forms of G glycoprotein from Hendra and Nipah virus. Further, the invention relates to therapeutic antibodies including neutralizing antibodies, and vaccines for the prevention and treatment of infection by Hendra and Nipah viruses.Type: GrantFiled: June 22, 2012Date of Patent: June 16, 2015Assignee: The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.Inventors: Christopher C. Broder, Katharine N. Bossart
-
Patent number: 9050322Abstract: This invention relates generally to identifying peptide sequences involved in antibody binding to any protein for synthesis of vaccine treatments. This novel method allows for a more manageable vaccine peptide discovery and specific generation of unique immunogenic peptides from self-tumor associated proteins and/or foreign proteins from infectious organisms for specific and/or enhanced expression only in the presence of the antibody.Type: GrantFiled: February 22, 2013Date of Patent: June 9, 2015Assignee: The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.Inventors: Sathibalan Ponniah, George E Peoples, Catherine E Storrer, Michael Flora
-
Patent number: 9045532Abstract: This invention relates to soluble forms of G glycoprotein from Hendra and Nipah virus. In particular, this invention relates to compositions comprising soluble forms of G glycoprotein from Hendra and Nipah virus and also to diagnostic and therapeutic methods using the soluble forms of G glycoprotein from Hendra and Nipah virus. Further, the invention relates to therapeutic antibodies including neutralizing antibodies, and vaccines for the prevention and treatment of infection by Hendra and Nipah viruses.Type: GrantFiled: June 22, 2012Date of Patent: June 2, 2015Assignee: The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.Inventors: Christopher C. Broder, Katharine N. Bossart
-
Patent number: 8968738Abstract: Methods of using anti-FceRI or anti-IgE antibodies for treating an autoimmune disease are disclosed. Also disclosed is a composition comprising an anti-FceRI antibody or anti-IgE antibody for use in treating an autoimmune disease. Also disclosed are non-antibody compounds that specifically activate basophils and/or mast cells, either by cross-linking IgE or FceRI, or by activating the cells through an FceRI-independent pathway and methods of using the same to treat autoimmune diseases.Type: GrantFiled: September 14, 2011Date of Patent: March 3, 2015Assignee: The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.Inventors: Edward E. Mitre, Marc P. Hübner
-
Patent number: 8969529Abstract: The invention is based on the discovery of the epitope in the Stx2 protein for the 11 E1O antibody. The invention features compositions containing non-full length Stx2 polypeptides that include the 11 E1O monoclonal antibody epitope. The invention also features methods of producing anti-Stx2 antibodies specific for the 11 E1O epitope of the Stx2 protein. Additionally, the invention features methods for treating a subject having, or at risk of developing, a Shiga toxin associated disease (e.g., hemolytic uremia syndrome and diseases associated with E. coli and S. dysenteriae infection) with a polypeptide that includes the 11 E1O epitope or with an anti-Stx2 antibody developed using the methods of the invention. Furthermore, the invention features the detection of Stx2 in a sample using the antibodies developed using the methods of the invention.Type: GrantFiled: January 21, 2010Date of Patent: March 3, 2015Assignee: The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.Inventors: Alison O'Brien, Angela Melton-Celsa, Michael Smith, James Sinclair
-
Publication number: 20150044670Abstract: The disclosure describes alterations in ERG gene expression. ERG isoforms and promoter sequence of the ERG gene that are involved in, or associated with, prostate cancer are provided. The disclosure further provides therapeutic compositions and methods of detecting, diagnosing, prognosing, and treating prostate cancer, including biomarkers for detecting the expression of two or more of the following genes: PSA/KLK3, PMEPA1, NKX3.1, ODC1, AMD1, and ERG.Type: ApplicationFiled: August 22, 2013Publication date: February 12, 2015Applicant: The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc.Inventors: Shiv Srivastava, Albert Dobi, Taduru Sreenath, Gyorgy Petrovics, Chen Sun
-
Patent number: 8945573Abstract: This invention relates generally to identifying peptide sequences involved in antibody binding to any protein for synthesis of vaccine treatments. This novel method allows for a more manageable vaccine peptide discovery and specific generation of unique immunogenic peptides from self-tumor associated proteins and/or foreign proteins from infectious organisms for specific and/or enhanced expression only in the presence of the antibody.Type: GrantFiled: March 10, 2008Date of Patent: February 3, 2015Assignee: The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.Inventors: Sathibalan Ponniah, George E. Peoples, Catherine E. Storrer, Michael Flora
-
Patent number: 8883164Abstract: This invention relates generally to identifying peptide sequences involved in antibody binding to any protein for synthesis of vaccine treatments. This novel method allows for a more manageable vaccine peptide discovery and specific generation of unique immunogenic peptides from self-tumor associated proteins and/or foreign proteins from infectious organisms for specific and/or enhanced expression only in the presence of the antibody.Type: GrantFiled: December 23, 2011Date of Patent: November 11, 2014Assignee: The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.Inventors: Sathibalan Ponniah, George E. Peoples, Catherine E. Storrer, Michael Flora
-
Patent number: 8871455Abstract: Methods and kits are provided for assessing radiation injury and exposure in a subject. The methods comprise measuring the levels of at least two (2) protein biomarkers from different biological pathways and correlating the levels with an assessment of radiation injury and exposure. Additional use of peripheral blood cell counts and serum enzyme biomarkers, evaluated in the early time frame after a suspected radiation exposure, and use of integrated multiple parameter triage tools to enhance radiation exposure discrimination and assessment are also provided. The information obtained from such methods can be used by a clinician to accurately assess the extent of radiation injury/exposure in the subject, and thus will provide a valuable tool for determining treatment protocols on a subject by subject basis.Type: GrantFiled: June 12, 2007Date of Patent: October 28, 2014Assignee: The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.Inventors: William Blakely, Natalia Ossetrova, Marcy Grace, Alexandra Miller, Jean Mulimbi Muderhwa, Glen Manglapus
-
Publication number: 20140315742Abstract: The present invention relates to methods and kits to assess an absorbed dose of ionizing radiation and/or the severity of tissue injury from radiation in a patient. The invention also relates to algorithms used to calculate an absorbed dose of radiation based on biomarker measurements of a plurality of biomarkers that are altered relative to a normal control in the event of radiation exposure.Type: ApplicationFiled: September 28, 2012Publication date: October 23, 2014Applicants: MESO SCALE TECHNOLOGIES, LLC, THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC.Inventors: William F Blakely, Eli N. Glezer, John Kenten, Sudeep Kumar, Anu Mathew, Natalia I. Ossetrova, George Sigal
-
Patent number: 8865171Abstract: This invention relates to soluble forms of G glycoprotein from Hendra and Nipah virus. In particular, this invention relates to compositions comprising soluble forms of G glycoprotein from Hendra and Nipah virus and also to diagnostic and therapeutic methods using the soluble forms of G glycoprotein from Hendra and Nipah virus. Further, the invention relates to therapeutic antibodies including neutralizing antibodies, and vaccines for the prevention and treatment of infection by Hendra and Nipah viruses.Type: GrantFiled: July 7, 2005Date of Patent: October 21, 2014Assignee: The Henry M. Jackson Foundation For the Advancement of Military Medicine, Inc.Inventors: Christopher C. Broder, Katharine N. Bossart
-
Patent number: 8858938Abstract: The present invention relates to monoclonal antibodies that bind or neutralize Hendra or Nipah virus. The invention provides such antibodies, fragments of such antibodies retaining Hendra or Nipah virus-binding ability, fully human antibodies retaining Hendra or Nipah virus-binding ability, and pharmaceutical compositions including such antibodies. The invention further provides for isolated nucleic acids encoding the antibodies of the invention and host cells transformed therewith. Additionally, the invention provides for prophylactic, therapeutic, and diagnostic methods employing the antibodies and nucleic acids of the invention.Type: GrantFiled: September 13, 2013Date of Patent: October 14, 2014Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, The Henry M. Jackson Foundation of the Advancement of Military Medicine, Inc.Inventors: Dimiter S. Dimitrov, Zhongyu Zhu, Christopher C. Broder
-
Patent number: 8858639Abstract: Embodiments relate to systems and methods for a cranial implant assembly adapted for insertion during a craniectomy procedure. In aspects, the inventive cranial implant assembly can contain a peripheral attachment member for attachment to the edge of a skull opening, as well as an articulated spanning member that over-arches and holds a cover in place over the opening. The articulated spanning member contains a central implant fastened or connected to a swollen dura in the skull opening. As swelling of the dura subsides, tension is exerted on guidewires in both the spanning member and cover to draw those constructs into a rigid state. The tips of the spanning member can gradually approach the peripheral attachment member, and register into place using a locking mechanism, such as a pair of opposing magnets. As a result, only one surgical operation or procedure Is required to both perform a craniectomy and implant a supporting assembly for eventual skull regeneration.Type: GrantFiled: July 29, 2011Date of Patent: October 14, 2014Assignee: The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.Inventor: Teodoro Aclan Tigno, Jr.